Not-for-profit hospitals are starting to get some relief after a tough three-year stretch of expenses outpacing weak revenue gains. They are getting better at cost-cutting, and revenue is starting to rise more rapidly.
Medicare and Medicaid have dramatically altered American life and all facets of the U.S. healthcare industry. The programs are poised to change significantly in the years ahead. Explore our special coverage marking their 50th anniversary.
A list of the largest publicly traded pharmaceutical companies, ranked by 2014 revenue reported to the U.S. Securities and Exchange Commission and other sources. Source: Modern Healthcare reporting. Published May 25, 2015. p. 50
Antibiotic prescriptions were as frequent among doctors providing care through a telemedicine appointment as physicians who saw patients face-to-face, a new study found. But the types of antibiotics prescribed via telemedicine could increase antimicrobial resistance.
The federal government is loosely capping the profits of Medicaid managed-care insurers. But many large companies already live within the proposed ratio, raising questions about the regulation's influence.
A slew of new quality standards outlined in the 653-page proposed CMS rules are meant to modernize Medicaid managed-care regulation and improve quality of care. But cash-strapped state agencies might not be able to manage the load, experts say.
Texas Health Resources continued to demonstrate that it has fully recovered from last year's brush with the Ebola virus, which had only a fleeting impact on its financial performance. The system achieved a higher operating margin in the first quarter of this year as it saw more patients.
The first update in more than a decade to Medicaid managed-care rules seeks to fill a funding gap left by Congress in promoting the use of electronic health-record systems by long-term care, behavioral health and other providers.
Federal investigators are reportedly probing medical devices linked to spreading cancer in women and examining what Johnson & Johnson, at one time the largest manufacturer of laparoscopic power morcellators, knew about the dangers before pulling them from the market in 2014.